Deutsche Bank AG boosted its holdings in Aclaris Therapeutics (NASDAQ:ACRS) by 29.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 179,622 shares of the biotechnology company’s stock after buying an additional 40,784 shares during the quarter. Deutsche Bank AG owned 0.58% of Aclaris Therapeutics worth $4,426,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new position in Aclaris Therapeutics in the 3rd quarter worth about $142,000. Teacher Retirement System of Texas bought a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $200,000. Landscape Capital Management L.L.C. bought a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $307,000. Caxton Corp grew its stake in shares of Aclaris Therapeutics by 76.8% during the 4th quarter. Caxton Corp now owns 17,994 shares of the biotechnology company’s stock valued at $444,000 after purchasing an additional 7,818 shares during the period. Finally, Granite Investment Partners LLC bought a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $565,000. 92.19% of the stock is owned by institutional investors and hedge funds.
A number of research firms have issued reports on ACRS. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Monday, January 8th. Leerink Swann cut their price target on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating for the company in a research note on Tuesday, March 13th. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Aclaris Therapeutics currently has an average rating of “Hold” and an average price target of $43.50.
Aclaris Therapeutics stock opened at $17.62 on Monday. The stock has a market cap of $545.72, a price-to-earnings ratio of -7.05 and a beta of 1.63. Aclaris Therapeutics has a 52-week low of $16.01 and a 52-week high of $33.10.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million. equities research analysts anticipate that Aclaris Therapeutics will post -4.27 earnings per share for the current year.
In related news, Director Stephen A. Tullman acquired 26,700 shares of the business’s stock in a transaction that occurred on Friday, April 6th. The stock was bought at an average cost of $16.54 per share, for a total transaction of $441,618.00. Following the purchase, the director now owns 157,507 shares in the company, valued at approximately $2,605,165.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Neal Walker acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The shares were bought at an average price of $16.75 per share, with a total value of $167,500.00. Following the completion of the purchase, the insider now owns 897,184 shares in the company, valued at approximately $15,027,832. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 37,950 shares of company stock valued at $629,856. 16.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics (ACRS) Holdings Boosted by Deutsche Bank AG” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/16/aclaris-therapeutics-acrs-holdings-boosted-by-deutsche-bank-ag.html.
Aclaris Therapeutics Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.